A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

This is an open-label, Phase 1b dose escalation and expansion study of OMP-305B83 plus
FOLFIRI or FOLFOX to evaluate the safety, efficacy, and pharmacokinetics of OMP-305B83 in
combination with FOLFIRI or FOLFOX in patients with metastatic Colorectal Cancer. This study
consists of a screening period, a treatment period, and a post-treatment follow-up period in
which patients will be followed for survival for up to 5 years. Patients will be enrolled in
two stages: a dose-escalation stage and an expansion phase.

Inclusion Criteria:

- Measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1

- Age >21 years

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Adequate organ and marrow function

- For women of childbearing potential and men with partners of childbearing potential,
agreement (by patient and/or partner) to use two effective forms of contraception from
study entry through at least 6 months after the termination visit.

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Receiving any other investigational agents or any other anti-cancer therapy

- Receiving prior hepatic intra-arterial chemotherapy

- Known significant clinically significant gastrointestinal disease

- Patients with brain metastases (treated or untreated) leptomeningeal disease,
uncontrolled seizure disorder, or active neurologic disease

- Significant intercurrent illness that will limit the patient's ability to participate
in the study or may result in their death over the next 18 months

- Pregnant or nursing women

- Inability to comply with study and follow up procedure